Mylan Gets Until April 2020 To Decide On Biosimilar Botox Collaboration With Revance

 
• By Akriti Seth
  
2020
Revance extends Mylan’s deadline to April 2020 in exchange for $5m • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business